1. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. (27th May 2021) Authors: Zabana Abdo, Y; Marín-Jiménez, I; Rodríguez-Lago, I; Vera, I; Martín, M D; Guerra, I; Gisbert, J P; Mesonero, F; Benítez, O; Taxonera, C; Ponferrada-Díaz, Á; Piqueras, M; Lucendo, A; Caballol, B; Mañosa, M; Martínez-Montiel, P; Bosca-Watts, M; Gordillo, J; Bujanda, L; Manceñido, N Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S078 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P127 Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study). (25th January 2019) Authors: Bastida, G; Marín-Jiménez, I; Forés, A; García-Planella, E; Argüelles-Arias, F; Sarasa, P; Tagarro, I; Fernández-Nistal, A; Montoto, C; Aguas, M; Santos-Fernández, J; Boscá, M; Ferreiro-Iglesias, R; Merino, O; Aldeguer, X; Cortés, X; Sicilia, B; Mesonero, F; Barreiro-de Acosta, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P309 Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study. (25th January 2019) Authors: Marín-Jiménez, I; Bastida, G; Forés, A; García-Planella, E; Argüelles-Arias, F; Sarasa, P; Tagarro, I; Fernández-Nistal, A; Montoto, C; Aguas, M; Santos-Fernández, J; Boscá, M; Ferreiro-Iglesias, R; Merino, O; Aldeguer, X; Cortés, X; Sicilia, B; Mesonero, F; Barreiro-de Acosta, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P335 Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data. (25th January 2019) Authors: Guerra Veloz, M; Belvis Jimenez, M; Valdes Delgado, T; Castro Laria, L; Maldonado Pérez, B; Benítez Roldán, A; Perea Amarillo, R; Merino Bohorquez, V; Calleja Hernandez, M A; Caunedo Álvarez, A; Vilches Arenas, A; Argüelles-Arias, F Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P381 Predictors of vedolizumab response to induction: Real-life experience. (16th January 2018) Authors: Gutiérrez, A; Sempere, L; Belvis, M; Vázquez, J M; Laveda, R; García, M; Argüelles-Arias, F; Pallarés, H; Castro, L; Gómez, E; Maldonado, B Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P391 Are cut-off ranges of Infliximab serum levels in Crohn's disease always the same in clinical practice?. (25th January 2019) Authors: Valdes Delgado, T; Guerra Veloz, M; Belvis Jimenez, M; Maldonado Pérez, B; Castro Laria, L; Benítez Roldán, A; Perea Amarillo, R; Merino Bohorquez, V; Calleja Hernandez, M A; Ortiz, T; Caunedo Álvarez, A; Vilches Arenas, A; Saez Diaz, A; Argüelles-Arias, F Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S303 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry. (25th January 2019) Authors: Casanova, M J; Chaparro, M; Mínguez, M; Ricart, E; Taxonera, C; García-López, S; Guardiola, J; López-San Román, A; Iglesias, E; Beltrán, B; Sicilia, B; Vera, M I; Hinojosa, J; Riestra, S; Domènech, E; Calvet, X; Pérez-Calle, J L; Martín-Arranz, M D; Aldeguer, X; Rivero, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P478 Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study. (27th May 2021) Authors: Olmedo-Martín, R; Martín-Rodríguez, M D M; Lorenzo-González, L; Lázaro-Sáez, M; Lopez-Vico, M; Hernández-Martínez, Á; Argüelles-Arias, F; Vázquez-Morón, J M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P493 Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease. (16th January 2018) Authors: Guerra Veloz, M F; Belvis Jimenez, M; Valdes Delgado, T; Perea Amarillo, R; Castro Laria, L; Maldonado Pérez, B; Merino, V; Benítez Roldán, A; Caunedo Álvarez, A; Argüelles-Arias, F Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S354 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P519 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results. (16th January 2018) Authors: Guerra Veloz, M F; Belvis Jimenez, M; Vázquez Morón, J M; Pallarés Manrique, H; Valdes Delgado, T; Castro Laria, L; Maldonado Pérez, B; Perea Amarillo, R; Merino, V; Caunedo Álvarez, A; Argüelles-Arias, F Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗